Details of the Drug

General Information of Drug (ID: DMA2NYS)

Drug Name
Lampalizumab
Indication
Disease Entry ICD 11 Status REF
Geographic retinal atrophy 9B78.9 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB11826
TTD ID
DM7Z6Y

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement factor D (CFD) TT8D13I CFAD_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02745119) Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT). U.S. National Institutes of Health.
2 In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95.